| MeSH term | MeSH ID | Detail |
|---|---|---|
| Nephrotic Syndrome | D009404 | 11 associated lipids |
| Brain Ischemia | D002545 | 89 associated lipids |
| Leukemia, Myeloid | D007951 | 52 associated lipids |
| Ischemia | D007511 | 18 associated lipids |
| Glycosuria | D006029 | 10 associated lipids |
| Seizures | D012640 | 87 associated lipids |
| Neuromuscular Diseases | D009468 | 10 associated lipids |
| Nerve Degeneration | D009410 | 53 associated lipids |
| Peptic Ulcer | D010437 | 19 associated lipids |
| Cystic Fibrosis | D003550 | 65 associated lipids |
tacrolimus
Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.
Cross Reference
Introduction
To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with tacrolimus?
tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
- Antimicrob. Agents Chemother. (2)
- Am. J. Physiol. Renal Physiol. (1)
- Drug Metab. Dispos. (1)
- Others (1)
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with tacrolimus
PubChem Associated disorders and diseases
What pathways are associated with tacrolimus
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with tacrolimus?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with tacrolimus?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with tacrolimus?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with tacrolimus?
Related references are published most in these journals:
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with tacrolimus?
There are no associated biomedical information in the current reference collection.
NCBI Entrez Crosslinks
All references with tacrolimus
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Troppmann C et al. | Higher surgical wound complication rates with sirolimus immunosuppression after kidney transplantation: a matched-pair pilot study. | 2003 | Transplantation | pmid:12883205 |
| Gaynor JJ and Ciancio G | The Importance of Using Serially Measured Tacrolimus Clearance Values, Especially During the Early Posttransplantation Period. | 2018 | Transplantation | pmid:29271869 |
| Ellis D et al. | Epstein-Barr virus-related disorders in children undergoing renal transplantation with tacrolimus-based immunosuppression. | 1999 | Transplantation | pmid:10532541 |
| Reutzel-Selke A et al. | Short-term immunosuppressive treatment of the donor ameliorates consequences of ischemia/ reperfusion injury and long-term graft function in renal allografts from older donors. | 2003 | Transplantation | pmid:12811235 |
| Molano RD et al. | Long-term islet allograft survival in nonobese diabetic mice treated with tacrolimus, rapamycin, and anti-interleukin-2 antibody. | 2003 | Transplantation | pmid:12811239 |
| Waldman WJ et al. | Inhibition of angiogenesis-related endothelial activity by the experimental immunosuppressive agent leflunomide. | 2001 | Transplantation | pmid:11707749 |
| Miroux C et al. | In vitro effects of cyclosporine A and tacrolimus on regulatory T-cell proliferation and function. | 2012 | Transplantation | pmid:22743548 |
| Jindal RM et al. | Effect of deoxyspergualin on the endocrine function of the rat pancreas. | 1993 | Transplantation | pmid:7504347 |
| Millis JM et al. | Tacrolimus for primary treatment of steroid-resistant hepatic allograft rejection. | 1996 | Transplantation | pmid:8629298 |
| Sheiner PA et al. | Increased risk of early rejection correlates with recovery of CD3 cell count after liver transplant in patients receiving OKT3 induction. | 1997 | Transplantation | pmid:9355846 |
| Karlsson H and Nässberger L | FK506 suppresses the mitogen-induced increase in lymphocyte adhesiveness to endothelial cells, but does not affect endothelial cell activation in response to inflammatory stimuli. | 1997 | Transplantation | pmid:9355847 |
| Reding R et al. | Conversion from cyclosporine to FK506 for salvage of immunocompromised pediatric liver allografts. Efficacy, toxicity, and dose regimen in 23 children. | 1994 | Transplantation | pmid:7507272 |
| Roberts JP et al. | Reversal of chronic rejection after treatment failure with FK506 and RS61443. | 1993 | Transplantation | pmid:7692634 |
| Storb R et al. | FK-506 and methotrexate prevent graft-versus-host disease in dogs given 9.2 Gy total body irradiation and marrow grafts from unrelated dog leukocyte antigen-nonidentical donors. | 1993 | Transplantation | pmid:7692635 |
| Cacciarelli TV et al. | Oral tacrolimus (FK506) induction therapy in pediatric orthotopic liver transplantation. | 1996 | Transplantation | pmid:8610416 |
| Egidi MF and Gaber AO | Outcomes of African-American kidney-transplant recipients treated with sirolimus, tacrolimus, and corticosteroids. | 2003 | Transplantation | pmid:12605133 |
| Osowski CL et al. | Evaluation of the drug interaction between intravenous high-dose fluconazole and cyclosporine or tacrolimus in bone marrow transplant patients. | 1996 | Transplantation | pmid:8610430 |
| Watanabe M et al. | Efficacy of DHMEQ, a NF-κB inhibitor, in islet transplantation: II. Induction DHMEQ treatment ameliorates subsequent alloimmune responses and permits long-term islet allograft acceptance. | 2013 | Transplantation | pmid:23860082 |
| Burroughs TE et al. | Increasing incidence of new-onset diabetes after transplant among pediatric renal transplant patients. | 2009 | Transplantation | pmid:19667939 |
| Jurcevic S et al. | A new enzyme-linked immunosorbent assay to measure anti-endothelial antibodies after cardiac transplantation demonstrates greater inhibition of antibody formation by tacrolimus compared with cyclosporine. | 1998 | Transplantation | pmid:9603168 |
| Kung L and Halloran PF | Immunophilins may limit calcineurin inhibition by cyclosporine and tacrolimus at high drug concentrations. | 2000 | Transplantation | pmid:10933159 |
| Beatty PR et al. | Effect of cyclosporine and tacrolimus on the growth of Epstein-Barr virus-transformed B-cell lines. | 1998 | Transplantation | pmid:9603175 |
| Macphee IA et al. | Tacrolimus pharmacogenetics: polymorphisms associated with expression of cytochrome p4503A5 and P-glycoprotein correlate with dose requirement. | 2002 | Transplantation | pmid:12490779 |
| Maes BD et al. | Differences in gastric motor activity in renal transplant recipients treated with FK-506 versus cyclosporine. | 1999 | Transplantation | pmid:10589943 |
| Shapiro AM et al. | Defining optimal immunosuppression for islet transplantation based on reduced diabetogenicity in canine islet autografts. | 2002 | Transplantation | pmid:12490784 |
| Mehra MR et al. | Ethnic disparity in clinical outcome after heart transplantation is abrogated using tacrolimus and mycophenolate mofetil-based immunosuppression. | 2002 | Transplantation | pmid:12490790 |
| Aulagnon F et al. | Diarrhea after kidney transplantation: a new look at a frequent symptom. | 2014 | Transplantation | pmid:25073040 |
| Tokita D et al. | High PD-L1/CD86 ratio on plasmacytoid dendritic cells correlates with elevated T-regulatory cells in liver transplant tolerance. | 2008 | Transplantation | pmid:18301333 |
| Niioka T et al. | Comparison of pharmacokinetics and pharmacogenetics of once- and twice-daily tacrolimus in the early stage after renal transplantation. | 2012 | Transplantation | pmid:23073468 |
| Gruessner RW and Sharp HL | Living-related intestinal transplantation: first report of a standardized surgical technique. | 1997 | Transplantation | pmid:9415566 |
| Swinnen LJ et al. | Prospective study of sequential reduction in immunosuppression, interferon alpha-2B, and chemotherapy for posttransplantation lymphoproliferative disorder. | 2008 | Transplantation | pmid:18645482 |
| Sureshkumar KK and Chopra B | In search of an optimal induction agent in kidney transplantation. | 2014 | Transplantation | pmid:24978038 |
| Sommerer C et al. | Individualized monitoring of nuclear factor of activated T cells-regulated gene expression in FK506-treated kidney transplant recipients. | 2010 | Transplantation | pmid:20463649 |
| Froud T et al. | Islet transplantation with alemtuzumab induction and calcineurin-free maintenance immunosuppression results in improved short- and long-term outcomes. | 2008 | Transplantation | pmid:19104407 |
| Tan HP et al. | Pediatric living donor kidney transplantation under alemtuzumab pretreatment and tacrolimus monotherapy: 4-year experience. | 2008 | Transplantation | pmid:19104412 |
| Curran CF et al. | Acute overdoses of tacrolimus. | 1996 | Transplantation | pmid:8932293 |
| Reyes J et al. | Long-term results after conversion from cyclosporine to tacrolimus in pediatric liver transplantation for acute and chronic rejection. | 2000 | Transplantation | pmid:10910279 |
| Yamauchi A et al. | Neurotoxicity induced by tacrolimus after liver transplantation: relation to genetic polymorphisms of the ABCB1 (MDR1) gene. | 2002 | Transplantation | pmid:12352921 |
| Radkowski M et al. | Detection of hepatitis C virus replication in peripheral blood mononuclear cells after orthotopic liver transplantation. | 1998 | Transplantation | pmid:9753352 |
| Ciancio G et al. | A randomized long-term trial of tacrolimus and sirolimus versus tacrolimus and mycophenolate mofetil versus cyclosporine (NEORAL) and sirolimus in renal transplantation. I. Drug interactions and rejection at one year. | 2004 | Transplantation | pmid:14742989 |
| Ciancio G et al. | A randomized long-term trial of tacrolimus/sirolimus versus tacrolimus/mycophenolate mofetil versus cyclosporine (NEORAL)/sirolimus in renal transplantation. II. Survival, function, and protocol compliance at 1 year. | 2004 | Transplantation | pmid:14742990 |
| van Hooff JP et al. | Tacrolimus and posttransplant diabetes mellitus in renal transplantation. | 2005 | Transplantation | pmid:15940032 |
| Warty V et al. | FK506: a novel immunosuppressive agent. Characteristics of binding and uptake by human lymphocytes. | 1988 | Transplantation | pmid:2458643 |
| Günther M et al. | Rapid decline of antibodies after hepatitis A immunization in liver and renal transplant recipients. | 2001 | Transplantation | pmid:11233913 |
| Ekberg H et al. | Relationship of tacrolimus exposure and mycophenolate mofetil dose with renal function after renal transplantation. | 2011 | Transplantation | pmid:21562449 |
| Rezeig MA et al. | Kaposi's sarcoma in liver transplant recipients on FK506: two case reports. | 1997 | Transplantation | pmid:9175820 |
| Kuypers DR et al. | Clinically relevant drug interaction between voriconazole and tacrolimus in a primary renal allograft recipient. | 2006 | Transplantation | pmid:16794545 |
| Foster RD et al. | Long-term acceptance of composite tissue allografts through mixed chimerism and CD28 blockade. | 2003 | Transplantation | pmid:14508367 |
| Talento A et al. | A single administration of LFA-1 antibody confers prolonged allograft survival. | 1993 | Transplantation | pmid:7679531 |
| Mor E et al. | Reversal of gastrointestinal toxicity associated with long-term FK506 immunosuppression by conversion to cyclosporine in liver transplant recipients. | 1994 | Transplantation | pmid:7513098 |